Dublin, Ireland (PRWEB) March 15, 2013
Over the last decade, genomics and proteomics have been used as key tools to discover potential drug targets and to better understand the complexities of biology. To balance research in these areas, metabolomics, a new science is evolving for analyzing the basic metabolic changes taking place in a living organism. Metabolomics is thus an emerging concept which refers to the systematic study of the distinctive chemical fingerprints generated in a particular cellular process.
The Global Metabolomics market is showing a double digit growth (CAGR 35%) due to supportive factors such as, (i) increased willingness of biotechnology and pharma companies to adopt metabolomics concept to drive R&D activity within the industry, (ii) rapid growth of metabolomics data analysis softwares and solutions, and (iii) the advancement of analytical technologies. Metabolomics is used in the identification of new biomarkers, which indicate a change in the physiological state of a cell or tissue. Biomarker screening is important in the process of new drug discovery, and is also a key in vitro diagnostics tool. Additionally it is also being used for environmental toxicology screening. While, there are major concerns of this market such as the validation challenges, the positive aspects may very well offset the market restraints to aid the market grow at an exceptional rate.
This report covers the market by disease indications along with the applications and metabolite profiling for biomarker discovery applications. In addition, it also includes the factors driving and restraining the market and covers the market scenario in the U.S., Europe, Asia and the Rest of the World (ROW). This report will provide the company profiles of key companies along with the competitive analysis.
Copyright©2012 Vocus, Inc.
All rights reserved